{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:45:09Z","timestamp":1791884709015,"version":"4.3.4"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Kidney involvement is a common and clinically significant complication of multiple myeloma (MM), with a subset of patients progressing to end-stage kidney disease (ESKD). Historically, kidney transplantation was considered contraindicated in MM due to poor prognosis and high relapse rates. However, the introduction of novel anti-myeloma therapies has markedly improved hematologic responses and patient survival, leading to reconsideration of transplantation in this population. This review summarizes current evidence on patient selection, optimal timing, and post-transplant management of kidney transplantation in MM. Candidate selection should be guided by disease biology, depth of hematologic response, and remission durability. Transplantation is preferentially considered in patients achieving at least very good partial response, ideally with minimal residual disease negativity, while timing should be individualized according to cytogenetic risk, remission duration, and overall disease stability. Post-transplant management requires balancing immunosuppression with the competing risks of relapse, infection, and graft rejection. The optimal role of maintenance therapy remains uncertain, particularly given the potential interaction between anti-myeloma agents and allograft immunity. Available evidence, derived mainly from retrospective studies and small cohorts, suggests that patient and graft outcomes in carefully selected MM patients may approach those observed in other causes of ESKD. Although important uncertainties remain, kidney transplantation should be considered a viable treatment option within a multidisciplinary framework. Future studies are needed to refine eligibility criteria, optimize timing, and define long-term management strategies in this evolving population.<\/jats:p>","DOI":"10.1093\/ckj\/sfag335","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:22:30Z","timestamp":1790266950000},"source":"Crossref","is-referenced-by-count":0,"title":["Kidney transplantation in multiple myeloma: patient selection, timing, and post-transplant challenges in the modern therapeutic era"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7039-4701","authenticated-orcid":false,"given":"Amir","family":"Shabaka","sequence":"first","affiliation":[{"name":"Nephrology Department, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"De\u00a0Soto","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ovidia","family":"L\u00f3pez-Oliva","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Azores-Moreno","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Jimenez-Martin","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"2026101304513177400_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van\u00a0de\u00a0Donk","year":"2021","journal-title":"Lancet"},{"key":"2026101304513177400_bib2","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.kint.2020.11.010","article-title":"Management of acute kidney injury in symptomatic multiple myeloma","volume":"99","author":"Bridoux","year":"2021","journal-title":"Kidney Int"},{"key":"2026101304513177400_bib3","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute kidney injury in patients with cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N Engl J Med"},{"key":"2026101304513177400_bib4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/ejh.70116","article-title":"Survival and renal recovery in newly diagnosed multiple myeloma patients presenting with dialysis-requiring severe renal impairment","volume":"116","author":"Sharma","year":"2026","journal-title":"Eur J Haematol"},{"key":"2026101304513177400_bib5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.clml.2021.01.015","article-title":"Clinical outcomes associated with chronic kidney disease in elderly medicare patients with multiple myeloma","volume":"21","author":"Li","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026101304513177400_bib6","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution","volume":"158","author":"Blad\u00e9","year":"1998","journal-title":"Arch Intern Med"},{"key":"2026101304513177400_bib7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/annonc\/mdt483","article-title":"Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents","volume":"25","author":"Dimopoulos","year":"2014","journal-title":"Ann Oncol"},{"key":"2026101304513177400_bib8","doi-asserted-by":"publisher","first-page":"12661","DOI":"10.1038\/s41598-026-43754-8","article-title":"Trends in renal failure-related mortality among U.S. multiple myeloma patients aged\u2009\u2265\u200945 years, 1999\u20132023: analysis of CDC data","volume":"16","author":"Jiang","year":"2026","journal-title":"Sci Rep"},{"key":"2026101304513177400_bib9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41408-026-01461-7","article-title":"Toward a cure for multiple myeloma within a decade","volume":"16","author":"Mohty","year":"2026","journal-title":"Blood Cancer J"},{"key":"2026101304513177400_bib10","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1097\/TP.0000000000002449","article-title":"Kidney transplant in the era of modern therapy for multiple myeloma","volume":"102","author":"Huskey","year":"2018","journal-title":"Transplantation"},{"key":"2026101304513177400_bib11","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/ndt\/gfz211","article-title":"Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry","volume":"36","author":"Courant","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026101304513177400_bib12","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1053\/j.ajkd.2016.12.023","article-title":"Kidney Transplantation for kidney failure due to multiple myeloma: case reports","volume":"69","author":"Le","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2026101304513177400_bib13","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/ndt\/gfac196","article-title":"Outcomes of kidney transplantation in patients with myeloma and amyloidosis in the USA","volume":"37","author":"Ng","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026101304513177400_bib14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2215\/CJN.06290615","article-title":"Trends in survival and renal recovery in patients with multiple myeloma or light-chain amyloidosis on chronic dialysis","volume":"11","author":"Decourt","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026101304513177400_bib15","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.kint.2025.07.011","article-title":"Management recommendations for kidney transplantation in patients with plasma cell dyscrasia","volume":"108","author":"Murakami","year":"2025","journal-title":"Kidney Int"},{"key":"2026101304513177400_bib16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/ckj\/sfz128","article-title":"Kidney transplantation for active multiple myeloma or smoldering myeloma: a case-control study","volume":"14","author":"Kormann","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026101304513177400_bib17","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ekir.2022.01.003","article-title":"Kidney Transplant Outcomes of Patients With Multiple Myeloma","volume":"7","author":"Heybeli","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026101304513177400_bib18","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1016\/j.clml.2021.11.002","article-title":"A new reality for multiple myeloma renal failure: US data report on kidney transplant outcomes","volume":"22","author":"Dykes","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026101304513177400_bib19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/ckj\/sfy137","article-title":"Risk of relapse of multiple myeloma following kidney transplantation","volume":"12","author":"Shah","year":"2019","journal-title":"Clin Kidney J"},{"key":"2026101304513177400_bib20","doi-asserted-by":"publisher","first-page":"101141","DOI":"10.1016\/j.xkme.2025.101141","article-title":"Chimeric antigen receptor T-cell therapy in dialysis-dependent patients with multiple myeloma: insights from a 5-case series","volume":"7","author":"Swamy","year":"2025","journal-title":"Kidney Med"},{"key":"2026101304513177400_bib21","first-page":"1571","article-title":"Impact of dialysis dependence on survival for multiple myeloma with renal impairment: a multicenter study in China","volume":"13","author":"Jian","year":"2023","journal-title":"Am J Cancer Res"},{"key":"2026101304513177400_bib22","doi-asserted-by":"publisher","first-page":"17588359251357682","DOI":"10.1177\/17588359251357682","article-title":"Dialysis dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study","volume":"17","author":"Wang","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"2026101304513177400_bib23","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026101304513177400_bib24","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3324\/haematol.2023.284662","article-title":"Role of minimal residual disease assessment in multiple myeloma","volume":"109","author":"Szalat","year":"2024","journal-title":"Haematologica"},{"key":"2026101304513177400_bib25","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026101304513177400_bib26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1182\/blood.2025029999","article-title":"High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing","volume":"147","author":"Schavgoulidze","year":"2026","journal-title":"Blood"},{"key":"2026101304513177400_bib27","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/ajh.27327","article-title":"High-risk multiple myeloma: redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy","volume":"99","author":"Rees","year":"2024","journal-title":"Am J Hematol"},{"key":"2026101304513177400_bib28","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1002\/ajh.70070","article-title":"European Myeloma Network consensus statement on functional high-risk multiple myeloma","volume":"100","author":"Lim","year":"2025","journal-title":"Am J Hematol"},{"key":"2026101304513177400_bib29","doi-asserted-by":"publisher","first-page":"e701","DOI":"10.1097\/TXD.0000000000001156","article-title":"Frailty and kidney transplantation: a systematic review and meta-analysis","volume":"7","author":"Quint","year":"2021","journal-title":"Transplant Direct"},{"key":"2026101304513177400_bib30","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026101304513177400_bib31","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/jcm11030672","article-title":"Outcomes of frail patients while waiting for kidney transplantation: differences between physical frailty phenotype and FRAIL scale","volume":"11","author":"P\u00e9rez-S\u00e1ez","year":"2022","journal-title":"J Clin Med"},{"key":"2026101304513177400_bib32","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC Expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Writing Committee","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026101304513177400_bib33","doi-asserted-by":"publisher","first-page":"ofac574","DOI":"10.1093\/ofid\/ofac574","article-title":"Cumulative incidence and relative risk of infection in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based regimens: a systematic review and meta-analysis","volume":"9","author":"Vassilopoulos","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026101304513177400_bib34","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026101304513177400_bib35","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1038\/s41598-023-27465-y","article-title":"Incidence and risk factors of opportunistic infections after autologous stem cell transplantation: a nationwide, population-based cohort study in Korea","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"2026101304513177400_bib36","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1111\/trf.13789","article-title":"International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing","volume":"56","author":"Chapuy","year":"2016","journal-title":"Transfusion"},{"key":"2026101304513177400_bib37","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1111\/trf.17137","article-title":"Anti-CD38 monoclonal antibody interference with blood compatibility testing: differentiating isatuximab and daratumumab via functional epitope mapping","volume":"62","author":"Chami","year":"2022","journal-title":"Transfusion"},{"key":"2026101304513177400_bib38","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"2026101304513177400_bib39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.05.022","article-title":"Impact of renal impairment and lymphodepletion regimen on outcomes after CAR T-Cell therapy in relapsed\/refractory multiple myeloma","author":"Grieb","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"2026101304513177400_bib40","doi-asserted-by":"publisher","DOI":"10.46883\/2026.25921166","article-title":"Emerging T-cell engagers and novel immunotargets in multiple myeloma","volume":"40","author":"Awadallah","year":"2026","journal-title":"Oncology"},{"key":"2026101304513177400_bib41","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/ndt\/gfv402","article-title":"Different impact of hemodialysis vintage on cause-specific mortality in long-term hemodialysis patients","volume":"31","author":"Sumida","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2026101304513177400_bib42","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1053\/j.ajkd.2024.04.012","article-title":"Frailty and duration of maintenance dialysis: a Japanese nationwide cross-sectional study","volume":"84","author":"Yamamoto","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026101304513177400_bib43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/s-0037-1606180","article-title":"The complications of vascular access in hemodialysis","volume":"44","author":"Masud","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"2026101304513177400_bib44","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/ndt\/gfp679","article-title":"Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study","volume":"25","author":"Tsakiris","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2026101304513177400_bib45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/nep.12985","article-title":"Changing survival of people with myeloma and end stage kidney disease: a cohort study using Australian and New Zealand dialysis and transplant registry 1963\u20132013","volume":"23","author":"Webster","year":"2018","journal-title":"Nephrology"},{"key":"2026101304513177400_bib46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/23993693251413641","article-title":"Clinical practice pattern of management of plasma cell dyscrasia for kidney transplant candidates and recipients in the United States","volume":"10","author":"Boppana","year":"2026","journal-title":"J Onco-Nephrol"},{"key":"2026101304513177400_bib47","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.kint.2020.07.012","article-title":"KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation","volume":"98","author":"Ma\u0142yszko","year":"2020","journal-title":"Kidney Int"},{"key":"2026101304513177400_bib48","doi-asserted-by":"publisher","first-page":"14343","DOI":"10.3389\/ti.2025.14343","article-title":"Targeting CD38 in antibody-mediated rejection","volume":"38","author":"Mayer","year":"2025","journal-title":"Transpl Int"},{"key":"2026101304513177400_bib49","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2026101304513177400_bib50","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1053\/j.ajkd.2022.11.010","article-title":"Daratumumab use prior to kidney transplant and T cell\u2013mediated rejection: a case report","volume":"81","author":"Scalzo","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2026101304513177400_bib51","doi-asserted-by":"publisher","first-page":"e1302","DOI":"10.1093\/cid\/ciaa1189","article-title":"Immunosuppressive agents and infectious risk in transplantation: managing the \u201cNet State of Immunosuppression\u201d","volume":"73","author":"Roberts","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026101304513177400_bib52","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1080\/10428194.2025.2551785","article-title":"The role of maintenance therapy and its cessation in patients with multiple myeloma","volume":"66","author":"Sneider","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"2026101304513177400_bib53","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1053\/j.ajkd.2016.11.024","article-title":"Acute kidney allograft rejection precipitated by lenalidomide treatment for multiple myeloma","volume":"69","author":"Lum","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2026101304513177400_bib54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.intimp.2018.12.035","article-title":"Thalidomide ameliorate graft chronic rejection in an allogenic kidney transplant model","volume":"71","author":"Zhang","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"2026101304513177400_bib55","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3349\/ymj.2022.63.2.158","article-title":"The Immunomodulating effects of thalidomide and dexamethasone in a murine cardiac allograft transplantation model","volume":"63","author":"Kim","year":"2022","journal-title":"Yonsei Med J"},{"key":"2026101304513177400_bib56","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/tri.13004","article-title":"Thalidomide treatment prevents chronic graft rejection after aortic transplantation in rats\u2014an experimental study","volume":"30","author":"Miller","year":"2017","journal-title":"Transpl Int"},{"key":"2026101304513177400_bib57","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4103\/ijot.ijot_90_24","article-title":"Bortezomib-based chemotherapy and bone-marrow followed by renal transplantation in multiple myeloma: a literature review","volume":"19","author":"Sethi","year":"2025","journal-title":"Indian J Transpl"},{"key":"2026101304513177400_bib58","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1016\/j.ekir.2025.07.009","article-title":"Anti-CD38 daratumumab treatment of chronic active antibody-mediated kidney allograft rejection","volume":"10","author":"Lye","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026101304513177400_bib59","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/TP.0000000000003247","article-title":"CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection","volume":"105","author":"Doberer","year":"2021","journal-title":"Transplantation"},{"key":"2026101304513177400_bib60","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ijpharm.2013.05.033","article-title":"From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation","volume":"452","author":"Knops","year":"2013","journal-title":"Int J Pharm"},{"key":"2026101304513177400_bib61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: cardiooncology state-of-the-art review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026101304513177400_bib62","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41408-024-01182-9","article-title":"Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review","volume":"14","author":"Chen","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026101304513177400_bib63","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/10815589251364807","article-title":"Bispecific T-cell engagers for relapsed\/refractory multiple myeloma after solid organ transplantation: a case series","volume":"74","author":"Gregg-Garcia","year":"2026","journal-title":"J Investig Med"},{"key":"2026101304513177400_bib64","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1053\/j.ajkd.2026.04.012","article-title":"Kidney transplantation post\u2013chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma","volume":"88","author":"Khan","year":"2026","journal-title":"Am J Kidney Dis"},{"key":"2026101304513177400_bib65","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3324\/haematol.2018.189159","article-title":"European myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when","volume":"103","author":"Caers","year":"2018","journal-title":"Haematologica"},{"key":"2026101304513177400_bib66","doi-asserted-by":"publisher","first-page":"7","DOI":"10.46989\/001c.160933","article-title":"Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group","volume":"8","author":"Chen","year":"2026","journal-title":"Clin Hematol Int"},{"key":"2026101304513177400_bib67","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"key":"2026101304513177400_bib68","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1515\/cclm-2015-1023","article-title":"Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation","volume":"54","author":"Willrich","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2026101304513177400_bib69","doi-asserted-by":"publisher","first-page":"111038","DOI":"10.1016\/j.clinbiochem.2025.111038","article-title":"Decoding the interference: how therapeutic monoclonal antibodies challenge serum protein electrophoresis and immunofixation","volume":"140","author":"Milandri","year":"2025","journal-title":"Clin Biochem"},{"key":"2026101304513177400_bib70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/blood-2020-136613","article-title":"Development of a Hydrashift 2\/4 Isatuximab assay to mitigate interference with monoclonal protein detection on immunofixation electrophoresis in vitro diagnostic tests in multiple myeloma","volume":"136","author":"Finn","year":"2020","journal-title":"Blood"},{"key":"2026101304513177400_bib71","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1515\/cclm-2024-0416","article-title":"Evaluating the HYDRASHIFT 2\/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma","volume":"62","author":"Lee","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"2026101304513177400_bib72","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.clml.2023.05.008","article-title":"Recommendations for management of secondary antibody deficiency in multiple myeloma","volume":"23","author":"Giralt","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026101304513177400_bib73","doi-asserted-by":"publisher","first-page":"106662","DOI":"10.1016\/j.ekir.2026.106662","article-title":"Mineral and bone disease in CKD and kidney transplantation: controversies, gaps, and a path forward","volume":"11","author":"Kanbay","year":"2026","journal-title":"Kidney Int Rep"},{"key":"2026101304513177400_bib74","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood.2019000775","article-title":"Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"2026101304513177400_bib75","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1097\/TP.0000000000003477","article-title":"Long-term outcomes of sequential hematopoietic stem cell transplantation and kidney transplantation: single-center experience","volume":"105","author":"Moreira","year":"2021","journal-title":"Transplantation"},{"key":"2026101304513177400_bib76","doi-asserted-by":"publisher","first-page":"9358","DOI":"10.3390\/ijms26199358","article-title":"Kidney transplantation in patients with multiple myeloma: current evidence, challenges, and future directions","volume":"26","author":"Rodrigues","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026101304513177400_bib77","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s12032-025-02753-x","article-title":"BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects","volume":"42","author":"Amin","year":"2025","journal-title":"Med Oncol"},{"key":"2026101304513177400_bib78","doi-asserted-by":"publisher","first-page":"e267004","DOI":"10.6004\/jnccn.2026.7004","article-title":"Incorporating the next generation of immunotherapies into the treatment of multiple myeloma","volume":"24","author":"Miller","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"key":"2026101304513177400_bib79","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/ndt\/gfae282","article-title":"Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial","volume":"40","author":"Akifova","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026101304513177400_bib80","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/TP.0000000000005257","article-title":"Blood gene expression profiling and donor-derived cell-free DNA to noninvasively diagnose clinical and subclinical kidney transplant rejection: a real-life appraisal study","volume":"109","author":"Sellar\u00e9s","year":"2025","journal-title":"Transplantation"},{"key":"2026101304513177400_bib81","doi-asserted-by":"publisher","first-page":"102407","DOI":"10.1016\/j.trim.2026.102407","article-title":"Advances in biosensors for monitoring immune responses and allograft rejection in organ transplantation","volume":"97","author":"Khosroshahi","year":"2026","journal-title":"Transpl Immunol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag335\/71382473\/sfag335.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/10\/sfag335\/71382473\/sfag335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/10\/sfag335\/71382473\/sfag335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:51:37Z","timestamp":1791881497000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag335\/8833852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":81,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag335","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,24]]},"article-number":"sfag335"}}